Potassium channel agonists emerging as treatment options for focal epilepsy: are we breaking new ground? - PubMed
6 hours ago
- #Focal Epilepsy
- #Precision Medicine
- #Kv7 Channel Agonists
- Focal epilepsy is a leading cause of neurological disability, with about one-third of patients failing to achieve seizure freedom despite available antiseizure medications (ASMs).
- Current therapies often broadly modulate synaptic transmission, leading to dose-limiting adverse effects like cognitive and psychiatric issues.
- Kv7 (KCNQ) potassium channels, which control the neuronal M-current, are a high-precision target for regulating intrinsic excitability and acting as a 'molecular brake' against pathological firing.
- The mini-review covers the clinical evolution of Kv7 modulation, from first-generation ezogabine to more selective second-generation candidates like azetukalner (XEN1101) and opakalim (BHV-7000).
- Kv7 agonists represent a mechanistically elegant approach to restoring seizure resistance, with second-generation agents showing encouraging proof-of-concept.
- Long-term success will depend on clear patient-centered advantages over established ASMs, and future value may lie in precision medicine for KCNQ2/3-related encephalopathies and managing neuropsychiatric comorbidities.